Phase 2 Study of Amivantamab Plus Lazertinib in Previously Treated Patients With EGFR-Mutant Lung Cancers With Brain and Leptomeningeal Metastases is a research paper published in Journal of Thoracic Oncology (2025). On theSindex it has a DataRank of 0.208. It has been cited 3 times, with 3 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.208
From this paper's citation signal
Citation Network Contribution
0
From 0 citing papers with measurable signal
This paper's DataRank is currently driven only by its base citation score. None of the citing papers had measurable citation signal.
Learn more about DataRank methodology →NCI NIH HHS
Grant: T32 CA009207
NCI NIH HHS
Grant: P30 CA008748
NCI NIH HHS
Grant: R01 CA245499
NCI NIH HHS
Grant: R01 CA264078
ASCO
Conquer Cancer Foundation
National Institutes of Health
FWCI
3.50
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords